BRENNEN

Industries / Health / Healthcare / Weight-loss clinics

Prescribing

Prescribing is the clinic's choice of which approved medicine a patient may get, within the limits of each drug's label, its supply and whoever pays for it.

7

Milestones achieved, from 1960s to 2025.

1

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1960s

    Rainbow pills off the market

    From the 1940s several US drug firms promoted "rainbow" diet pills, named for their bright and varied colors, to doctors and patients. By the 1960s the pills had caused dozens of deaths, and the FDA began removing them from the US market. P. A. Cohen of Harvard Medical School and his co-authors traced the same kind of pills to Spain and Brazil and back to the US, where they returned as weight-loss supplements laced with an amphetamine-like drug plus sedatives, beta-blockers and other medicines to mask its side effects.

    LessonA banned mixture can come back under a new label in another market.

    europepmc.org

    Credit

    the US Food and Drug Administration; P. A. Cohen, A. Goday and J. P. Swann, who traced the pills

  2. 1997

    Fen-phen withdrawn

    Fenfluramine and phentermine were each approved for obesity, but never as a pair, yet US prescriptions for the two drugs passed 18 million in 1996. In August 1997 H. M. Connolly and colleagues at the Mayo Clinic described unusual heart valve disease in 24 women who had taken the combination, five of whom had needed heart surgery. On 15 September 1997 the FDA asked for fenfluramine (Pondimin) and dexfenfluramine (Redux) to be withdrawn.

    LessonA combination prescribed to millions had never been tested as a combination.

    europepmc.orgfederalregister.gov

    Credit

    H. M. Connolly and colleagues, Mayo Clinic; FDA

  3. 2020

    A safety trial ends Belviq

    When the FDA approved lorcaserin (Belviq) in 2012, it required a trial of the drug's effect on the heart. That trial, CAMELLIA-TIMI 61, followed 12,000 patients and found no added heart risk, but cancer was diagnosed in 7.7% of patients on the drug against 7.1% on a placebo. On 13 February 2020 the FDA asked the maker, Eisai, to withdraw it.

    LessonA trial required to rule out one harm can find another.

    fda.gov

    Credit

    FDA; the CAMELLIA-TIMI 61 investigators

  4. 2021

    A weekly shot approved

    On 4 June 2021 the FDA approved Wegovy, the GLP-1 drug semaglutide given by injection once a week, for long-term weight management. In the STEP 1 trial of 1,961 adults without diabetes, weight fell by 14.9% over 68 weeks on the drug against 2.4% on placebo, counting everyone who started whether or not they kept taking it. Eli Lilly's tirzepatide, which acts on a second gut hormone as well, followed as Zepbound on 8 November 2023.

    api.fda.goveuropepmc.orgfda.gov

    Credit

    Novo Nordisk; J. P. H. Wilding and the STEP 1 investigators; Eli Lilly

  5. 2024

    A heart benefit approved

    On 8 March 2024 the FDA approved Wegovy to lower the risk of cardiovascular death, heart attack and stroke in adults with heart disease and obesity or overweight, the first weight-loss medicine with that use. In the trial behind it, which assigned more than 17,600 people to the drug or a placebo, such events occurred in 6.5% of those on Wegovy and 8% of those on placebo.

    fda.gov

    Credit

    FDA; Novo Nordisk, which ran the trial

  6. 2025

    England rations a rollout

    In December 2024 the National Institute for Health and Care Excellence (NICE), which decides what England's NHS pays for, recommended tirzepatide (Mounjaro) for obesity, and it estimated that 3.4 million people could qualify. Family doctors' practices could prescribe it from 23 June 2025, first only for people with a body mass index (BMI, weight in kilograms divided by height in meters squared) of 40 or more and at least four of five listed conditions, with 220,000 people to be treated in the first three years. An investigation by The BMJ found that by early September 2025 only 18 of 42 local commissioning bodies had started prescribing under the plan.

    LessonA national approval reaches patients only where local budgets pay for it.

    shropshiretelfordandwrekin.nhs.ukbmjgroup.com

    Credit

    NICE and NHS England; Elisabeth Mahase, The BMJ

  7. 2025

    The first pills approved

    On 22 December 2025 the FDA approved a once-daily pill form of Wegovy, the first GLP-1 medicine taken by mouth for obesity in the US. On 1 April 2026 it approved Lilly's orforglipron (Foundayo), a small-molecule pill that can be taken without food or water limits, after what the agency said was a 50-day review under a new program to shorten reviews. By then the Wegovy pill had passed 600,000 US prescriptions, the Associated Press reported, and Lilly set cash prices of $149 to $349 a month for Foundayo.

    mednous.comabc7news.com

    Credit

    Novo Nordisk; Eli Lilly; FDA

Watch for

  1. A third hormone added

    Lilly reports that retatrutide, an experimental weekly injection that acts on three hormone receptors (GIP, GLP-1 and glucagon), cut weight by an average of 25.0% at 80 weeks on the highest dose, against 3.9% on placebo, in its TRIUMPH-1 trial of 2,339 people, and by up to 22.6% in people with severe obesity and heart disease in TRIUMPH-3. Lilly plans to apply for US approval in the first quarter of 2027.

    Achieved whenfull results appear in a peer-reviewed journal and a regulator approves the drug.

    pharmaceutical-journal.combiospace.com

    Claimed by

    Eli Lilly, May and July 2026

Open

  1. 01

    A monthly price index

    A public monthly table of the cash price of one month's treatment with each approved obesity drug, brand and generic, injection and pill, in at least 15 countries, taken from published price lists and makers' published self-pay prices. Prices are converted to US dollars and adjusted for purchasing power, and each row gives the product, strength, pack, source and the date it was read. The table sets real prices beside published estimates of what generic semaglutide could cost.

    The brief
    Credit · unclaimed
  2. 02

    Safety actions, all regulators

    An open table, one row per action, of every approval, suspension, withdrawal and boxed warning (the strongest warning on a US label) for an obesity drug by the regulators of the US, the EU, the UK, Canada, Australia, Japan, India and Brazil, from the 1940s to now. Each row gives the date, the drug, the action, the stated reason and a link to the regulator's own record.

    The brief
    Credit · unclaimed

Open 01 · the brief

A monthly price index

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public monthly table of the cash price of one month's treatment with each approved obesity drug, brand and generic, injection and pill, in at least 15 countries, taken from published price lists and makers' published self-pay prices. Prices are converted to US dollars and adjusted for purchasing power, and each row gives the product, strength, pack, source and the date it was read. The table sets real prices beside published estimates of what generic semaglutide could cost.

Why it is still open

Prices moved quickly in 2026. Generic semaglutide went on sale in India in March, and Lilly set US cash prices of $149 to $349 a month for its new pill. KFF's 2023 comparison of US list prices with those of peer countries was a single snapshot, and The RX Index's 2026 tracker covers only US payment channels. J. Levi, A. Hill and colleagues estimated that generic semaglutide injections could be made and sold for $28 to $140 a person per year, but that study, like their 2023 survey of national prices, is also a snapshot. A search in November 2026 found no running public index across countries.

europepmc.orgkff.orgtherxindex.comthesouthfirst.com

Built with what exists

national price lists such as Japan's National Health Insurance drug price list, India's ceiling prices from its National Pharmaceutical Pricing Authority, the UK Drug Tariff and Canadian provincial formularies; makers' published self-pay prices; World Bank exchange-rate and purchasing-power data; a scheduled Python script that saves each month's snapshot to a GitHub repository.

  1. First step

    Record this month's published prices for semaglutide products in India, Canada, Japan, the UK and the US, with the source of each.

  2. Done looks like

    Twelve monthly snapshots covering at least 15 countries and every semaglutide, tirzepatide and orforglipron product sold in them, each price with a source link and the date read, and a published comparison of the lowest generic price in each country with the Levi estimate.

Open 02 · the brief

Safety actions, all regulators

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

An open table, one row per action, of every approval, suspension, withdrawal and boxed warning (the strongest warning on a US label) for an obesity drug by the regulators of the US, the EU, the UK, Canada, Australia, Japan, India and Brazil, from the 1940s to now. Each row gives the date, the drug, the action, the stated reason and a link to the regulator's own record.

Why it is still open

I. J. Onakpoya, C. J. Heneghan and J. K. Aronson counted 25 obesity drugs withdrawn for harms between 1964 and 2009, in a review that searched to December 2015, and found that case reports were the evidence cited in 80% of the withdrawals. Their list is a table in a paper, not a maintained dataset, and it ends before Belviq's withdrawal in 2020 and the new drugs' label changes. A search of Europe PMC in November 2026 found no update.

europepmc.orgfda.gov

Built with what exists

the Federal Register API and openFDA's label and Drugs@FDA endpoints; Health Canada's Drug Product Database API; the European Medicines Agency's published assessment and referral pages; an AI model such as Claude to draft rows from regulators' text, with each row checked by a person; a GitHub repository with a codebook.

  1. First step

    Rebuild Onakpoya's 25 withdrawals as rows, each with a link to the regulator's record.

  2. Done looks like

    The 25 withdrawals in Onakpoya's review rebuilt with a regulator source for each, plus every action since 2015 at all eight regulators, two people coding each regulator separately and agreeing on at least 90% of rows, published as a CSV file with its codebook.